Literature DB >> 8280186

The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein.

A D MBewu1, P N Durrington, S Bulleid, M I Mackness.   

Abstract

Lipoprotein(a) (Lp(a)) has close structural homology with plasminogen and, at least in vitro, may interfere with fibrinolysis. Any changes in the serum Lp(a) concentration during and following myocardial infarction (MI) and whether the serum Lp(a) level is affected by streptokinase (SK) are therefore of interest. Serum Lp(a) levels immediately before and 3 h after completion of an intravenous infusion of SK in 39 patients with acute MI were not significantly different (median 31.3 mg/dl before and 35.9 mg/dl after). Furthermore, SK added during the serum Lp(a) assay did not affect the result, except at very high concentrations of SK (1000 units/ml). Serum Lp(a) and fasting lipids were measured daily for 3 days following definite MI in 13 patients and then after 14 and 42 days. There was no significant change in serum Lp(a) following MI. In marked contrast, C-reactive protein levels in these patients increased steeply immediately following MI. Thus, there was no early 'acute-phase response' in serum Lp(a) levels after MI. However, greater variation in its concentration was observed at day 14 than at other times. Serum cholesterol, apolipoprotein B and apolipoprotein A1 concentrations decreased significantly following MI, whereas a significant transient increase in serum triglycerides occurred. Forty-two days after MI all lipid and lipoprotein values had regained their day 1 levels, except for apo A1, which remained depressed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280186     DOI: 10.1016/0021-9150(93)90040-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 2.  Drugs used in secondary prevention after myocardial infarction: case presentation.

Authors:  S Maxwell; W S Waring
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

3.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

4.  Lipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk.

Authors:  D J Byrne; I A Jagroop; H E Montgomery; M Thomas; D P Mikhailidis; N G Milton; A F Winder
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

5.  Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.

Authors:  Raul D Santos; Frederick J Raal; Alberico L Catapano; Joseph L Witztum; Elisabeth Steinhagen-Thiessen; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-01-22       Impact factor: 8.311

6.  Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction.

Authors:  A D MBewu; P N Durrington; M I Mackness; L Hunt; W H Turkie; J E Creamer
Journal:  Br Heart J       Date:  1994-04

7.  Lipoprotein(a): Cellular Effects and Molecular Mechanisms.

Authors:  Kirsten Riches; Karen E Porter
Journal:  Cholesterol       Date:  2012-09-06

8.  Lipoprotein(a) is associated with necrotic core progression of non-culprit coronary lesions in statin-treated patients with angina pectoris.

Authors:  Tsuyoshi Nozue; Shingo Yamamoto; Shinichi Tohyama; Kazuki Fukui; Shigeo Umezawa; Yuko Onishi; Tomoyuki Kunishima; Akira Sato; Toshihiro Nozato; Shogo Miyake; Youichi Takeyama; Yoshihiro Morino; Takao Yamauchi; Toshiya Muramatsu; Kiyoshi Hibi; Mitsuyasu Terashima; Ichiro Michishita
Journal:  Lipids Health Dis       Date:  2014-04-01       Impact factor: 3.876

Review 9.  Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.

Authors:  Ernest Choy; Kandeepan Ganeshalingam; Anne Grete Semb; Zoltán Szekanecz; Michael Nurmohamed
Journal:  Rheumatology (Oxford)       Date:  2014-06-06       Impact factor: 7.580

10.  Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK-mediated mechanisms.

Authors:  Kirsten Riches; Larissa Franklin; Azhar Maqbool; Michelle Peckham; Matthew Adams; Jacquelyn Bond; Philip Warburton; Nicole T Feric; Marlys L Koschinsky; David J O'Regan; Stephen G Ball; Neil A Turner; Karen E Porter
Journal:  Int J Biochem Cell Biol       Date:  2013-05-31       Impact factor: 5.085

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.